Search Results - "Soumerai, Jacob Drobnyk"

Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24) by Pagel, John M., Reddy, Nishitha, Jagadeesh, Deepa, Stathis, Anastasios, Asch, Adam Steven, Salman, Huda S., Kenkre, Vaishalee Padgaonkar, Soumerai, Jacob Drobnyk, Llorin-Sangalang, Judith, Gorbatchevsky, Igor, Li, Joanne, Zelenetz, Andrew David

“…Abstract only 7550 Background: FL patients (pts) with POD24 have poorer survival and may benefit from novel therapies at relapse. Zandelisib, a potent,…”
Get full text

TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) by Siddiqi, Tanya, Dorritie, Kathleen Anne, Soumerai, Jacob Drobnyk, Stephens, Deborah Marie, Dubovsky, Jason A, Gillenwater, Heidi H., Gong, Lucy, Thorpe, Jerill, Yang, Lin, Wierda, William G.

“…Abstract only 7501 Background: Eradication of MRD in CLL patients may be necessary for deep and durable responses. We assessed safety, pharmacokinetics, and…”
Get full text

Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies by Soumerai, Jacob Drobnyk, Jagadeesh, Deepa, Salman, Huda S., Lossos, Izidore S., Asch, Adam Steven, Reddy, Nishitha, Kenkre, Vaishalee Padgaonkar, Pagel, John M., Persky, Daniel O, Awan, Farrukh Tauseef, Magid Diefenbach, Catherine S., Huang, Wenying, Llorin-Sangalang, Judith, Gorbatchevsky, Igor, Zelenetz, Andrew David

“…Abstract only 7553 Background: Dual inhibition of PI3Kδ and BTK pathways may overcome existing or acquired monotherapy resistance. Dual inhibition of these…”
Get full text

Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax by Soumerai, Jacob Drobnyk, Mato, Anthony R., Carter, Jason, Dogan, Ahmet, Hochberg, Ephraim, Barnes, Jeffrey A., Hamilton, Audrey M., Abramson, Jeremy S., Batlevi, Connie Lee, Joffe, Erel, Matasar, Matthew J., Noy, Ariela, Owens, Colette Ngozi, Palomba, Maria Lia, Takvorian, Tak, Flaherty, Kelsey, Ramos, Lauren, Roeker, Lindsey Elizabeth, Abdel-Wahab, Omar Ibrahim, Zelenetz, Andrew David

“…Abstract only 8006 Background: Venetoclax (Ven)-Obinutuzumab (O) is approved for chronic lymphocytic leukemia (CLL) achieving frequent undetectable minimum…”
Get full text

Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) by Soumerai, Jacob Drobnyk, Pagel, John M., Jagadeesh, Deepa, Salman, Huda S., Kenkre, Vaishalee Padgaonkar, Asch, Adam Steven, Stathis, Anastasios, Reddy, Nishitha M., Iasonos, Alexia, Ghalie, Richard, Zelenetz, Andrew David

“…Abstract only…”
Get full text

An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies by Soumerai, Jacob Drobnyk, Barrientos, Jacqueline Claudia, Hallek, Michael, Kipps, Thomas J., Jones, Jeffrey Alan, Stilgenbauer, Stephan, Xing, Guan, Yao, Nai-Shun, Ysebaert, Loic, Zelenetz, Andrew David

“…Abstract only…”
Get full text